Chilton Capital Management’s Perspective Therapeutics CATX Stock Holding History

Chilton Capital Management’s Portfolio CATX Stock Details CATX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-50	Closed	-$137	–	607
2023 Q3	$137	Hold	50	–	–	﹤0.01%	502
2023 Q2	$334	Hold	50	–	–	﹤0.01%	529
2023 Q1	$319	Buy	+50	New	+$204	﹤0.01%	533
2022 Q3	–	Sell	-50	Closed	–	–	270
2022 Q2	$0	Buy	+50	New	+$153	﹤0.01%	623
2022 Q1	–	Sell	-50	Closed	–	–	280
2021 Q4	$0	Buy	+50	New	+$267	﹤0.01%	649

Other funds holding CATX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RAG

RIA Advisory Group Des Moines, Iowa $421M AUM 30.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

OCM

Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Chilton Capital Management's CATX Position: Q4 2023 in Review

Chilton Capital Management sold out of Perspective Therapeutics (CATX) in Q4 2023, closing a stake of 50 shares — an estimated $137 sold.

Chilton Capital Management first reported a position in CATX in Q4 2021 and held it in 5 quarters. The position peaked at $334 in Q2 2023. 52 funds tracked by Wall St. Rank hold CATX as of Q4 2023.

Chilton Capital Management reported no remaining Perspective Therapeutics position as of Q4 2023 after selling out during the quarter.
Chilton Capital Management sold 50 Perspective Therapeutics shares in Q4 2023, an estimated $137.
Chilton Capital Management first reported a position in Perspective Therapeutics in Q4 2021 and held it in 5 quarters.
Chilton Capital Management's Perspective Therapeutics position peaked at $334 in Q2 2023.
52 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q4 2023.

Based on Chilton Capital Management's 13F filing for Q4 2023, filed 18 Jan 2024.